激动剂-话题@MedSci

#激动剂#

173篇内容 | 3332人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627786, encodeId=2213162e786c7, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=2019 BSE/BHVS/TES立场声明：应用多巴胺激动剂治疗高催乳素血症患者超声心动图检查和监测, objectType=article, longId=162491, objectId=c97f1624919f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97f1624919f, replyNumber=0, likeNumber=24, createdTime=2019-03-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97f1624919f, moduleTitle=2019 BSE/BHVS/TES立场声明：应用多巴胺激动剂治疗高催乳素血症患者超声心动图检查和监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c97f1624919f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627785, encodeId=fc3f162e78584, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究, objectType=article, longId=161610, objectId=ccc41616101d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccc41616101d, replyNumber=0, likeNumber=27, createdTime=2019-03-06, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccc41616101d, moduleTitle=2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccc41616101d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627784, encodeId=015d162e784bc, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161211, objectId=849816121109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849816121109, replyNumber=0, likeNumber=74, createdTime=2019-02-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849816121109, moduleTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849816121109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627783, encodeId=b876162e7836a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161199, objectId=4d8e16119952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8e16119952, replyNumber=0, likeNumber=71, createdTime=2019-02-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8e16119952, moduleTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8e16119952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627782, encodeId=2e12162e78296, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Care.：胰高血糖素样肽-1受体激动剂是否增加糖尿病视网膜病变风险？, objectType=article, longId=159916, objectId=fef6159916b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6159916b0, replyNumber=0, likeNumber=50, createdTime=2019-02-15, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6159916b0, moduleTitle=Diabetes Care.：胰高血糖素样肽-1受体激动剂是否增加糖尿病视网膜病变风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6159916b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627781, encodeId=df12162e78157, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, objectType=article, longId=159719, objectId=117f159e19e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117f159e19e4, replyNumber=0, likeNumber=82, createdTime=2019-02-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117f159e19e4, moduleTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117f159e19e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627780, encodeId=b225162e7802d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Dent Res：脂联素受体激动剂减少2型糖尿病牙周炎, objectType=article, longId=158994, objectId=69ad15899461, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69ad15899461, replyNumber=0, likeNumber=74, createdTime=2019-01-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69ad15899461, moduleTitle=J Dent Res：脂联素受体激动剂减少2型糖尿病牙周炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69ad15899461)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627779, encodeId=a7ec162e779a9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Dent Res：脂连素受体激动剂减弱II型糖尿病患者的牙周炎, objectType=article, longId=158246, objectId=f841158246d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f841158246d1, replyNumber=0, likeNumber=81, createdTime=2019-01-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f841158246d1, moduleTitle=J Dent Res：脂连素受体激动剂减弱II型糖尿病患者的牙周炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f841158246d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627778, encodeId=b426162e778f1, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=国内鸟苷酸环化酶激动剂令泽舒®获批，将填补我国IBS-C治疗空白, objectType=article, longId=158122, objectId=e7da1581223a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7da1581223a, replyNumber=0, likeNumber=90, createdTime=2019-01-17, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7da1581223a, moduleTitle=国内鸟苷酸环化酶激动剂令泽舒®获批，将填补我国IBS-C治疗空白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7da1581223a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627777, encodeId=e291162e77748, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Neurol Clin Pract：多巴胺激动剂治疗最小意识状态, objectType=article, longId=157937, objectId=ad6b15e93775, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad6b15e93775, replyNumber=0, likeNumber=41, createdTime=2019-01-14, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad6b15e93775, moduleTitle=Neurol Clin Pract：多巴胺激动剂治疗最小意识状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad6b15e93775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627776, encodeId=b7c0162e77613, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, objectType=article, longId=155614, objectId=db9d15561414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db9d15561414, replyNumber=0, likeNumber=59, createdTime=2018-12-13, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db9d15561414, moduleTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db9d15561414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627775, encodeId=b955162e775fe, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=GUT：术前给予5-HT4受体激动剂普卢卡必利可以减少术后肠梗阻的发生, objectType=article, longId=155011, objectId=cfa615501112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa615501112, replyNumber=0, likeNumber=70, createdTime=2018-12-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa615501112, moduleTitle=GUT：术前给予5-HT4受体激动剂普卢卡必利可以减少术后肠梗阻的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa615501112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627774, encodeId=1938162e774d0, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Nat Chem Bio|张健/陈国强合作组等利用变构技术发现SIRT6激动剂或可用于肝癌治疗——陈凯先院士点评, objectType=article, longId=152395, objectId=7f3015239501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f3015239501, replyNumber=0, likeNumber=77, createdTime=2018-11-01, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f3015239501, moduleTitle=Nat Chem Bio|张健/陈国强合作组等利用变构技术发现SIRT6激动剂或可用于肝癌治疗——陈凯先院士点评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f3015239501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627773, encodeId=aeba162e7732a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Gastroenterology：FXR激动剂不依赖FGF19而使胆汁酸的合成减少, objectType=article, longId=151118, objectId=c4c11511183d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4c11511183d, replyNumber=0, likeNumber=25, createdTime=2018-10-17, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4c11511183d, moduleTitle=Gastroenterology：FXR激动剂不依赖FGF19而使胆汁酸的合成减少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4c11511183d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627772, encodeId=2338162e772e6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JCEM：胰高血糖素样肽-1受体激动剂对下丘脑-垂体-肾上腺轴的影响, objectType=article, longId=150287, objectId=f97e15028ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f97e15028ec4, replyNumber=0, likeNumber=31, createdTime=2018-10-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f97e15028ec4, moduleTitle=JCEM：胰高血糖素样肽-1受体激动剂对下丘脑-垂体-肾上腺轴的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f97e15028ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627771, encodeId=64d9162e77136, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, objectType=article, longId=149977, objectId=93781499e7e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93781499e7e4, replyNumber=0, likeNumber=83, createdTime=2018-09-30, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93781499e7e4, moduleTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93781499e7e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627770, encodeId=2191162e770a5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=两个新一代促血小板生成素受体激动剂获准, objectType=article, longId=147458, objectId=eeb414e4583d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eeb414e4583d, replyNumber=0, likeNumber=55, createdTime=2018-08-27, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeb414e4583d, moduleTitle=两个新一代促血小板生成素受体激动剂获准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeb414e4583d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627769, encodeId=0762162e7691a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=全球糖尿病超长效GLP-1抗体激动剂在中国获批临床, objectType=article, longId=146518, objectId=2f051465185b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f051465185b, replyNumber=0, likeNumber=86, createdTime=2018-08-14, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f051465185b, moduleTitle=全球糖尿病超长效GLP-1抗体激动剂在中国获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f051465185b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627768, encodeId=544c162e7689f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Obes Metab：胰高血糖素样肽1受体激动剂与2型糖尿病患者的微血管结局, objectType=article, longId=145630, objectId=143e145630e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=143e145630e4, replyNumber=0, likeNumber=23, createdTime=2018-08-03, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=143e145630e4, moduleTitle=Diabetes Obes Metab：胰高血糖素样肽1受体激动剂与2型糖尿病患者的微血管结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=143e145630e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627767, encodeId=8266162e767a3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes：选择性Epac激动剂可恢复2型糖尿病胰岛的葡萄糖诱导的Cdc42-Pak1激活和胰岛素分泌, objectType=article, longId=145124, objectId=cdac145124aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdac145124aa, replyNumber=0, likeNumber=64, createdTime=2018-07-26, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdac145124aa, moduleTitle=Diabetes：选择性Epac激动剂可恢复2型糖尿病胰岛的葡萄糖诱导的Cdc42-Pak1激活和胰岛素分泌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdac145124aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

2019 BSE/BHVS/TES立场声明：应用多巴胺激动剂治疗高催乳素血症患者超声心动图检查和监测

2019-03-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

2019年ASCO-SITC会议：Nektar Therapeutics公布新型Toll样受体激动剂NKTR-262的剂量递增研究

2019-03-06

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Care.：胰高血糖素样肽-1受体激动剂是否增加糖尿病视网膜病变风险？

2019-02-15

仁者大医 (审核中...)

前往app查看评论内容

#激动剂#

BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？

2019-02-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Dent Res：脂联素受体激动剂减少2型糖尿病牙周炎

2019-01-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Dent Res：脂连素受体激动剂减弱II型糖尿病患者的牙周炎

2019-01-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

国内鸟苷酸环化酶激动剂令泽舒®获批，将填补我国IBS-C治疗空白

2019-01-17

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Neurol Clin Pract：多巴胺激动剂治疗最小意识状态

2019-01-14

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加

2018-12-13

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

GUT：术前给予5-HT4受体激动剂普卢卡必利可以减少术后肠梗阻的发生

2018-12-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Nat Chem Bio|张健/陈国强合作组等利用变构技术发现SIRT6激动剂或可用于肝癌治疗——陈凯先院士点评

2018-11-01

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Gastroenterology：FXR激动剂不依赖FGF19而使胆汁酸的合成减少

2018-10-17

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JCEM：胰高血糖素样肽-1受体激动剂对下丘脑-垂体-肾上腺轴的影响

2018-10-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病

2018-09-30

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

两个新一代促血小板生成素受体激动剂获准

2018-08-27

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

全球糖尿病超长效GLP-1抗体激动剂在中国获批临床

2018-08-14

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Obes Metab：胰高血糖素样肽1受体激动剂与2型糖尿病患者的微血管结局

2018-08-03

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes：选择性Epac激动剂可恢复2型糖尿病胰岛的葡萄糖诱导的Cdc42-Pak1激活和胰岛素分泌

2018-07-26

科室
- - 订阅+
  - 更多科室
工具
服务